clinical trial · NCT07465198
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
Biocells Medical·phase2·not yet recruiting·n = 50
MSA - Multiple System AtrophyMSAMSCsPlacebo
brief summary
This study investigates the safety and efficacy of autologous stem cell therapy in patients with Multiple System Atrophy (MSA), a rare and progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The trial will evaluate functional outcomes, motor performance, and quality of life compared to placebo/controlled group.
started
Sep 1, 2026
primary completion
Sep 1, 2029
completion
Mar 1, 2031
last updated
Mar 11, 2026
official title
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Autologous Stem Cell Therapy in Patients With Multiple System Atrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol